To make medicines available to patients more quickly, Pfizer Global Supply is evolving from traditional batch to continuous manufacturing processes for certain Pfizer products.
Pfizer’s first Portable Continuous Miniature Modular (PCMM) manufacturing platform for solid oral dose medicines was used for the development and launch of an oncology product – shortening the manufacturing process from weeks to minutes.
Pfizer continues to advance our PCMM platform, making important strides in 2019.
Three other clinical candidates are being manufactured on the PCMM platform in Groton, Connecticut, and Freiburg, Germany. Pfizer estimates that 70% of its small molecule, solid oral dose portfolio will be manufactured on PCMM – yielding shorter cycle times, faster technology transfers and reduced process variability – within the next 10 years.
Share this page
